Crescita Therpeutc (TSE:CTX) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Crescita Therapeutics has announced an exclusive agreement to distribute the MicronJet 600, the world’s smallest intradermal delivery device, in Canada’s medical aesthetics market. The device promises precise, minimally invasive, and comfortable injections, an innovation welcomed by practitioners and patients. It is already CE marked and FDA cleared, with Crescita planning a Canadian launch in the first half of 2025, post Health Canada approval.
For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.